Suche
Mein Konto
Innovation award for cutting-edge research: Dr. Kalinin excellent!
Dr. Dmitrii Kalinin from the University of Münster will receive the 2025 Innovation Prize for his groundbreaking research in pharmaceutical chemistry.
Innovation award for cutting-edge research: Dr. Kalinin excellent!
Dr. Dmitrii Kalinin from Institute for Pharmaceutical and Medicinal Chemistry at the University of Münster was awarded the Medical/Pharmaceutical Chemistry Innovation Prize 2025. The prize, worth 5,000 euros, is awarded by the Medical Chemistry Section of the German Chemical Society (GDCh) and the Pharmaceutical/Medical Chemistry Section of the German Pharmaceutical Society (DPhG).
This award recognizes outstanding scientific publications and results in medicinal and pharmaceutical chemistry. Kalinin received the honor for his significant research into novel inhibitors of factor XIIa. These innovative approaches could open up new therapeutic possibilities in anticoagulant therapy.
Recognition for innovative research
The importance of Kalinin's work is highlighted by his numerous published articles in high-ranking international journals. He has been a junior group leader at the Institute for Pharmaceutical and Medicinal Chemistry in Münster since 2018 and has already had a notable influence on the research field there.
His academic career includes studying pharmacy at the Pharmaceutical Academy in Perm, Russia. In addition, Kalinin can look back on international research experience in Australia, Denmark and Germany. His doctorate, carried out as part of the Cells in Motion graduate school at the University of Münster, treated hydroxamates as inhibitors of Zn²⁺-dependent enzymes.
Kalinin's research currently focuses on innovative molecular approaches to inhibit coagulation factor XIIa. This could potentially support the development of new, safe anticoagulants.
The innovation award in the research community
The innovation prize, which was awarded online for the first time during FiMC 2021, aims to reward exemplary achievements in research. Previous award winners include Prof. Dr. Pierre Koch and Ass.-Prof. Dr. Nina Schützenmeister, who were honored for their original and pioneering work. Koch developed selective kinase inhibitors for the treatment of neurodegenerative diseases, while Schützenmeister developed innovative synthesis methods for biologically active natural products.
The work that distinguishes Kalinin represents a continuation of this trajectory by also opening up new perspectives in medicinal chemistry and underscoring the importance of research achievements for the further development of therapies.
Overall, Kalinin's award shows not only the researcher's personal success, but also the outstanding position of the University of Münster in the field of medicinal and pharmaceutical chemistry. In addition, the interdisciplinary collaboration that is promoted at the university, for example through the graduate school “Chemical Biology of Ion Channels”, becomes visible. This program has received funding of 4.5 million euros for its second funding period and is concerned with the study of small organic molecules that influence the function of ion channels.
The interdisciplinary orientation and the promotion of young scientists are central elements of the research strategy at the University of Münster, as the DFG-funded graduate colleges show. These ensure that the next generation of scientists is best prepared for their challenges.